US / ETF
Franklin Genomic Advancements ETF
HELX
Market price
$43.79
Source / date
Yahoo Finance chart · 10/2/2026, 7:59:51 PM
Exchange-traded prices may be delayed or unavailable from the quote provider. Company P/E-based scores, DCF valuation and forensic analysis do not apply to this listing; the analysis below uses the framework appropriate to its investment type.
DeepScreen investment analysis
ETF basket analysis
Refreshed 2026-10-04 16:17:50 UTC
Analysis is cached for up to 30 minutes; quote and disclosure dates can differ from retrieval time.
Latest provider market price
USD 43.79
Observation: 2026-10-02 19:59:51 UTC · May be delayed
View Yahoo Finance source ↗Adjusted-price history (USD)
2026-10-02 · 43.79
Period change 36.44%
Observed drawdown -17.59%
53 observations · 2025-10-06 to 2026-10-02. Calculated over displayed observations; missing dates are not interpolated. Latest bar may be incomplete.
What the available data shows
The latest one-year historical return is 35.54%. The worst observed decline from a prior peak over the available trailing three-year window was -25.71%. History ends 2026-10-02; these observations are not a forecast.
Reported top holdings account for 48.5% of assets. Reported annual expense ratio: 0.50%. Price returns alone do not measure tracking quality. A matching benchmark and aligned NAV dates are needed to assess tracking error and premium or discount.
Basket and structure
What the ETF owns and how the reported portfolio is classified.
- Benchmark / index
- Health
- Fund family
- Franklin Templeton, Inc
- Provider listing name
- Franklin Genomic Advancements ETF
- Legal structure
- Exchange Traded Fund
- Inception
- 2020-02-25
- First recorded trade
- 2020-02-27
Market listing label; not a verified fund-family disclosure.
Provider's first available trade, not necessarily fund launch.
Price history
Returns and risk calculated from available adjusted-price history, not a benchmark comparison.
- 1Y return
- 35.54%
- 3Y annualized return
- 15.82%
- 5Y annualized return
- -3%
- 3Y rolling median
- -5.86%
- 5Y rolling median
- -3.68%
- 52-week high
- $44.89
- 52-week low
- $31.24
Holding quality and valuation
Weighted fundamentals are calculated only across holdings for which usable company fundamentals are available.
- Weighted ROE
- -21.54%
- Weighted earnings growth
- 237.99%
- Weighted debt / equity
- 2.92
48.5% of reported weight covered.
Risk and concentration
Portfolio concentration plus realized and provider-published risk statistics.
- Top-10 weight
- 48.5%
- Largest sector
- healthcare · 96.5%
- Top-3 sector weight
- 100%
- 3Y max drawdown
- -25.71%
- 5Y max drawdown
- -53.09%
- 3Y volatility
- 21.85%
- Beta
- 1.02
Cost and execution
Ownership cost, tracking quality and exchange-trading friction where the source publishes them.
- Expense ratio / TER
- 0.5%
- Bid / ask spread
- 10.38%
- Premium / discount to NAV
- -0.16%
- AUM
- $31.54M
- Average volume
- 4.27K
- Latest session volume
- 3.78K
Not an average.
Top reported holdings
| Holding | Symbol | Weight |
|---|---|---|
| Guardant Health Inc | GH | 9.14% |
| Natera Inc | NTRA | 8.4% |
| Krystal Biotech Inc | KRYS | 5.8% |
| Adaptive Biotechnologies Corp | ADPT | 4.4% |
| Ligand Pharmaceuticals Inc | LGND | 4.29% |
| Twist Bioscience Corp | TWST | 4% |
| BridgeBio Pharma Inc | BBIO | 3.41% |
| United Therapeutics Corp | UTHR | 3.14% |
| Travere Therapeutics Inc Ordinary Shares | TVTX | 3.04% |
| Vertex Pharmaceuticals Inc | VRTX | 2.86% |
DeepScreen displays verified values returned by its current sources. Metrics without a verified value are omitted rather than shown as empty placeholder cards.
ETF news · HELX
UPDATINGLoading live headlines…
Stories mentioning this investment are shown only when the provider supplies a publication time within the past 24 hours. Headlines refresh every minute while this page is open.
Investment FAQ
Questions about Franklin Genomic Advancements ETF
Research answers for Franklin Genomic Advancements ETF (HELX) using the analysis framework appropriate to a ETF.
ETF FAQ
- What is Franklin Genomic Advancements ETF (HELX)?
- Franklin Genomic Advancements ETF is listed by DeepScreen as an exchange-traded fund. An ETF represents a portfolio of underlying assets while its units trade on an exchange during market hours. Research the fund's benchmark or strategy, holdings, concentration, costs, tracking quality and trading liquidity rather than evaluating it as a single operating company.
- How should I analyze Franklin Genomic Advancements ETF?
- Analyze Franklin Genomic Advancements ETF as a basket. Check what index or strategy it follows, the weight of its largest holdings and sectors, portfolio valuation and quality where meaningful, historical drawdown and volatility, expense ratio, tracking difference, tracking error, bid-ask spread, AUM, volume and premium or discount to NAV.
- What tracking metrics matter for Franklin Genomic Advancements ETF?
- For a benchmark-tracking ETF, compare both tracking difference and tracking error. Tracking difference shows how far the fund's return has lagged or exceeded its benchmark over a period, while tracking error measures how variable that gap has been. Fees, cash holdings, rebalancing and implementation costs can affect both.
- Is Franklin Genomic Advancements ETF a good ETF to buy?
- DeepScreen does not provide a personalized buy recommendation. Assess whether Franklin Genomic Advancements ETF's benchmark or strategy, concentration, costs, tracking, liquidity and risk fit the exposure you are researching, and verify the issuer's latest factsheet and prospectus before making an investment decision.